BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 6988911)

  • 21. [A randomized study of adjuvant treatments for operable breast cancer patients stratified by estrogen receptor and menopausal status].
    Nomura Y; Tsutsui S; Murakami S; Takenaka Y
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):643-9. PubMed ID: 10234295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of diethylstilbestrol and medroxyprogesterone acetate on kinetics and production of testosterone and dihydrotestosterone in patients with prostatic carcinoma.
    Nolten WE; Sholiton LJ; Srivastava LS; Knowles HC; Werk EE
    J Clin Endocrinol Metab; 1976 Dec; 43(6):1226-33. PubMed ID: 1002814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications].
    Mauriac L; Durand M; Bonichon F; Chauvergne J
    Bull Cancer; 1986; 73(2):148-54. PubMed ID: 2942203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Endocrine treatment of metastasizing breast cancer in menopausal women. A randomized comparison between tamoxifen (Nolvadex) versus tamoxifen and medroxyprogesterone acetate (Clinovir)].
    Mouridsen HT; Ellemann K; Mattsson W; Palshof T; Daehnfeldt J; Rose C
    Ugeskr Laeger; 1979 Jul; 141(31):2113-6. PubMed ID: 483409
    [No Abstract]   [Full Text] [Related]  

  • 25. [Experimental multihormone therapy on human breast carcinomas grown in nude mice].
    Fukutomi T
    Nihon Geka Gakkai Zasshi; 1989 Dec; 90(12):2021-30. PubMed ID: 2626154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.
    Pannuti F; Martoni A; Piana E; Tomasi L; Grieco A; Farris A; Saccani F; Baroni M
    Chemioterapia; 1984 Aug; 3(4):211-5. PubMed ID: 6241846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
    Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
    J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer stratified by estrogen receptors.
    Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
    Cancer; 1988 Jun; 61(11):2168-75. PubMed ID: 3130175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
    Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
    Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estrogen and progesterone receptors of adenomyosis in postmenopausal breast cancer patients treated with tamoxifen.
    Cohen I; Shapira J; Beyth Y; Bernheim J; Tepper R; Cordoba M; Altaras MM
    Gynecol Obstet Invest; 1998; 45(2):126-31. PubMed ID: 9517806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective sequential administration of tamoxifen and medroxyprogesterone acetate for 7,12-dimethylbenz[a-anthracene-induced rat mammary tumors in relation to hormone receptors.
    Tominaga T; Yoshida Y; Kitamura M; Kosaki G
    Jpn J Cancer Res; 1985 Nov; 76(11):1120-5. PubMed ID: 2935517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
    Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA
    Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers].
    Wada T; Matunami N; Houjou T; Morikawa E; Mori N; Nakano K; Aizawa M; Kurooka K; Kadota K; Yamato M
    Gan To Kagaku Ryoho; 1989 May; 16(5):2087-92. PubMed ID: 2525004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
    Muss HB; Case LD; Atkins JN; Bearden JD; Cooper MR; Cruz JM; Jackson DV; O'Rourke MA; Pavy MD; Powell BL
    J Clin Oncol; 1994 Aug; 12(8):1630-8. PubMed ID: 8040675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endocrine ablation for metastatic breast cancer: a reappraisal of hormone receptors.
    Moseley HS; Peetz ME; Keenan EJ; Awrich AE; Fletcher WS
    Am J Surg; 1980 Jul; 140(1):164-72. PubMed ID: 7396080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer.
    Jordan VC; Fritz NF; Tormey DC
    Cancer Res; 1987 Jan; 47(2):624-30. PubMed ID: 3098415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro growth regulation of endometrial carcinoma cells by tamoxifen and medroxyprogesterone acetate.
    Grenman SE; Roberts JA; England BG; Grönroos M; Carey TE
    Gynecol Oncol; 1988 Jun; 30(2):239-50. PubMed ID: 2967231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis.
    Peethambaram PP; Ingle JN; Suman VJ; Hartmann LC; Loprinzi CL
    Breast Cancer Res Treat; 1999 Mar; 54(2):117-22. PubMed ID: 10424402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial.
    Glick JH; Creech RH; Torri S; Holroyde C; Brodovsky H; Catalano RB; Varano M
    Cancer; 1980 Feb; 45(4):735-41. PubMed ID: 6986969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.